The safety and efficacy of anti-CD19 CAR-T cell products are being examined in various rheumatic disorders, including SLE, SLE-LN, SSc, IIM, pSS, AAV, RA, and APS. This evidence concerns the gene CD19 and rheumatoid arthritis.